On Oct 26, major Wall Street analysts update their ratings for $DexCom (DXCM.US)$, with price targets ranging from $85 to $115.
J.P. Morgan analyst Robbie Marcus downgrades to a hold rating, and adjusts the target price from $145 to $85.
BofA Securities analyst Travis Steed maintains with a buy rating.
Citi analyst Joanne Wuensch maintains with a buy rating.
Wells Fargo analyst Larry Biegelsen maintains with a buy rating, and adjusts the target price from $80 to $90.
Jefferies analyst Matthew Taylor maintains with a buy rating, and adjusts the target price from $160 to $100.
Furthermore, according to the comprehensive report, the opinions of $DexCom (DXCM.US)$'s main analysts recently are as follows:
DexCom has effectively bolstered investor confidence in its revenue target for 2025, which includes a minimal contribution from Stelo. It is anticipated that earnings estimates may rise in response to the company's return to double-digit revenue growth.
DexCom's third-quarter revenue outperformance was propelled by a record number of new patient initiations, yet earnings were affected by diminished gross margins. Momentum for DexCom is gathering as the year concludes, with a clear trajectory towards achieving at least a 15% year-over-year growth by 2025.
DexCom's third-quarter sales surpassed expectations, driven by a stronger than anticipated performance internationally, although the U.S. figures fell short relative to estimates. This discrepancy in the U.S. market is attributed to a decrease in new patient additions in the second quarter and anticipated effects from product mix. The company's guidance for sales and margins remains steady for 2024, in line with their targets for 2025.
Here are the latest investment ratings and price targets for $DexCom (DXCM.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月26日，多家华尔街大行更新了$德康医疗 (DXCM.US)$的评级，目标价介于85美元至115美元。
摩根大通分析师Robbie Marcus下调至持有评级，并将目标价从145美元下调至85美元。
美银证券分析师Travis Steed维持买入评级。
花旗分析师Joanne Wuensch维持买入评级。
富国集团分析师Larry Biegelsen维持买入评级，并将目标价从80美元上调至90美元。
富瑞集团分析师Matthew Taylor维持买入评级，并将目标价从160美元下调至100美元。
此外，综合报道，$德康医疗 (DXCM.US)$近期主要分析师观点如下：
德康医疗有效地增强了投资者对其在2025年营收目标的信恳智能，其中包括对Stelo的最低贡献。预计随着公司回归两位数营收增长，盈利预估可能会上升。
德康医疗第三季度营收表现强劲，受到创纪录的新增患者启动推动，但盈利受到毛利率降低的影响。随着年底临近，德康医疗的势头正在积聚，朝着至少在2025年实现15%的年度增长的明确轨迹。
德康医疗第三季度销售超出预期，主要得益于国际业绩强于预期，尽管美国数据相对预估有所不足。美国市场的这种差异归因于第二季度新增患者数量减少以及产品组合带来的预期影响。公司对2024年销售和利润率的引导保持稳定，符合2025年的目标。
以下为今日7位分析师对$德康医疗 (DXCM.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
